Literature DB >> 23236229

Way back for fructose and liver metabolism: bench side to molecular insights.

Alba Rebollo1, Núria Roglans, Marta Alegret, Juan C Laguna.   

Abstract

The World Health Organization recommends that the daily intake of added sugars should make up no more than 10% of total energy. The consumption of sugar-sweetened beverages is the main source of added sugars. Fructose, together with glucose, as a component of high fructose corn syrups or as a component of the sucrose molecule, is one of the main sweeteners present in this kind of beverages. Data from prospective and intervention studies clearly point to high fructose consumption, mainly in the form of sweetened beverages, as a risk factor for several metabolic diseases in humans. The incidence of hypertension, nonalcoholic fatty liver disease (NAFLD), dyslipidemia (mainly hypertriglyceridemia), insulin resistance, type 2 diabetes mellitus, obesity, and the cluster of many of these pathologies in the form of metabolic syndrome is higher in human population segments that show high intake of fructose. Adolescent and young adults from low-income families are especially at risk. We recently reviewed evidence from experimental animals and human data that confirms the deleterious effect of fructose on lipid and glucose metabolism. In this present review we update the information generated in the past 2 years about high consumption of fructose-enriched beverages and the occurrence of metabolic disturbances, especially NAFLD, type 2 diabetes mellitus, and metabolic syndrome. We have explored recent data from observational and experimental human studies, as well as experimental data from animal and cell models. Finally, using information generated in our laboratory and others, we provide a view of the molecular mechanisms that may be specifically involved in the development of liver lipid and glucose metabolic alterations after fructose consumption in liquid form.

Entities:  

Keywords:  Clinical studies; Dyslipidemia; Experimental studies; Hypertension; Metabolic syndrome; Nonalcoholic fatty liver disease; Obesity; Sweetened beverages

Mesh:

Substances:

Year:  2012        PMID: 23236229      PMCID: PMC3516224          DOI: 10.3748/wjg.v18.i45.6552

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  71 in total

Review 1.  Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk.

Authors:  Vasanti S Malik; Barry M Popkin; George A Bray; Jean-Pierre Després; Frank B Hu
Journal:  Circulation       Date:  2010-03-23       Impact factor: 29.690

2.  Sugar-sweetened beverages and risk of obesity and type 2 diabetes: epidemiologic evidence.

Authors:  Frank B Hu; Vasanti S Malik
Journal:  Physiol Behav       Date:  2010-02-06

Review 3.  Current treatment of non-alcoholic fatty liver disease.

Authors:  Mohamed H Ahmed; Christopher D Byrne
Journal:  Diabetes Obes Metab       Date:  2008-06-16       Impact factor: 6.577

Review 4.  Metabolic effects of fructose and the worldwide increase in obesity.

Authors:  Luc Tappy; Kim-Anne Lê
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

5.  Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A.

Authors:  Ricardo Rodríguez-Calvo; Emma Barroso; Lucía Serrano; Teresa Coll; Rosa M Sánchez; Manuel Merlos; Xavier Palomer; Juan C Laguna; Manuel Vázquez-Carrera
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

Review 6.  Hepatic lipid metabolism and non-alcoholic fatty liver disease.

Authors:  P Tessari; A Coracina; A Cosma; A Tiengo
Journal:  Nutr Metab Cardiovasc Dis       Date:  2009-04-08       Impact factor: 4.222

7.  Suppressor of cytokine signaling-3 (SOCS-3) and a deficit of serine/threonine (Ser/Thr) phosphoproteins involved in leptin transduction mediate the effect of fructose on rat liver lipid metabolism.

Authors:  Laia Vilà; Núria Roglans; Marta Alegret; Rosa María Sánchez; Manuel Vázquez-Carrera; Juan Carlos Laguna
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

Review 8.  Inflammation in atherosclerosis: transition from theory to practice.

Authors:  Peter Libby; Yoshihisa Okamoto; Viviane Z Rocha; Eduardo Folco
Journal:  Circ J       Date:  2010-01-09       Impact factor: 2.993

Review 9.  Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.

Authors:  Timothy A Yap; Michelle D Garrett; Mike I Walton; Florence Raynaud; Johann S de Bono; Paul Workman
Journal:  Curr Opin Pharmacol       Date:  2008-08-27       Impact factor: 5.547

10.  Fructose consumption as a risk factor for non-alcoholic fatty liver disease.

Authors:  Xiaosen Ouyang; Pietro Cirillo; Yuri Sautin; Shannon McCall; James L Bruchette; Anna Mae Diehl; Richard J Johnson; Manal F Abdelmalek
Journal:  J Hepatol       Date:  2008-03-10       Impact factor: 25.083

View more
  18 in total

1.  Resveratrol decreases fructose-induced oxidative stress, mediated by NADPH oxidase via an AMPK-dependent mechanism.

Authors:  Pei-Wen Cheng; Wen-Yu Ho; Yu-Ting Su; Pei-Jung Lu; Bo-Zone Chen; Wen-Han Cheng; Wen-Hsien Lu; Gwo-Ching Sun; Tung-Chen Yeh; Michael Hsiao; Ching-Jiunn Tseng
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

Review 2.  Adverse metabolic effects of dietary fructose: results from the recent epidemiological, clinical, and mechanistic studies.

Authors:  Kimber L Stanhope; Jean-Marc Schwarz; Peter J Havel
Journal:  Curr Opin Lipidol       Date:  2013-06       Impact factor: 4.776

3.  Aegle marmelos differentially affects hepatic markers of glycolysis, insulin signalling pathway, hypoxia, and inflammation in HepG2 cells grown in fructose versus glucose-rich environment.

Authors:  H Aggarwal; J Nair; P Sharma; R Sehgal; U Naeem; P Rajora; R Mathur
Journal:  Mol Cell Biochem       Date:  2017-08-01       Impact factor: 3.396

Review 4.  Health effects of fructose and fructose-containing caloric sweeteners: where do we stand 10 years after the initial whistle blowings?

Authors:  Luc Tappy; Kim-Anne Lê
Journal:  Curr Diab Rep       Date:  2015-08       Impact factor: 4.810

5.  Fructose Mediated Non-Alcoholic Fatty Liver Is Attenuated by HO-1-SIRT1 Module in Murine Hepatocytes and Mice Fed a High Fructose Diet.

Authors:  Komal Sodhi; Nitin Puri; Gaia Favero; Sarah Stevens; Charles Meadows; Nader G Abraham; Rita Rezzani; Hayden Ansinelli; Edward Lebovics; Joseph I Shapiro
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

6.  How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?

Authors:  Alireza Ghaemi; Fourugh Azam Taleban; Azita Hekmatdoost; Alireza Rafiei; Vahid Hosseini; Zohreh Amiri; Reza Homayounfar; Hafez Fakheri
Journal:  Hepat Mon       Date:  2013-12-07       Impact factor: 0.660

Review 7.  Simple sugar intake and hepatocellular carcinoma: epidemiological and mechanistic insight.

Authors:  Juan Carlos Laguna; Marta Alegret; Núria Roglans
Journal:  Nutrients       Date:  2014-12-22       Impact factor: 5.717

8.  AAV8-mediated Sirt1 gene transfer to the liver prevents high carbohydrate diet-induced nonalcoholic fatty liver disease.

Authors:  Laia Vilà; Ivet Elias; Carles Roca; Albert Ribera; Tura Ferré; Alba Casellas; Ricardo Lage; Sylvie Franckhauser; Fatima Bosch
Journal:  Mol Ther Methods Clin Dev       Date:  2014-10-01       Impact factor: 6.698

9.  Fructose: a key factor in the development of metabolic syndrome and hypertension.

Authors:  Zeid Khitan; Dong Hyun Kim
Journal:  J Nutr Metab       Date:  2013-05-25

Review 10.  Fructation in vivo: detrimental and protective effects of fructose.

Authors:  H M Semchyshyn
Journal:  Biomed Res Int       Date:  2013-07-24       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.